COL2A1_HUMAN,Q29D,0.567,Loss of Pyrrolidone carboxylic acid at Q24 (Pr = 0.25 | P = 7.5e-04); Gain of Disulfide linkage at C34 (Pr = 0.19 | P = 0.02); Altered Transmembrane protein (Pr = 0.13 | P = 0.02), None,-
COL2A1_HUMAN,S33N,0.281,-,-,-
COL2A1_HUMAN,V35L,0.168,-,-,-
COL2A1_HUMAN,V35M,0.224,-,-,-
COL2A1_HUMAN,D37S,0.341,-,-,-
COL2A1_HUMAN,R40S,0.555,Gain of Loop (Pr = 0.27 | P = 0.04); Altered Transmembrane protein (Pr = 0.25 | P = 1.6e-03); Gain of Sulfation at Y41 (Pr = 0.01 | P = 0.04), PS00006|PS00008,-
COL2A1_HUMAN,E50S,0.623,Loss of SUMOylation at K48 (Pr = 0.24 | P = 0.01); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000136|ELME000153|ELME000159,-
COL2A1_HUMAN,R53K,0.438,-,-,-
COL2A1_HUMAN,T61A,0.256,-,-,-
COL2A1_HUMAN,I68V,0.123,-,-,-
COL2A1_HUMAN,V72M,0.058,-,-,-
COL2A1_HUMAN,C75I,0.750,Loss of Disulfide linkage at C75 (Pr = 0.15 | P = 0.03), ELME000136|ELME000146|ELME000155|ELME000159|PS01208,-
COL2A1_HUMAN,C75V,0.762,Gain of Loop (Pr = 0.28 | P = 0.01); Loss of Disulfide linkage at C75 (Pr = 0.15 | P = 0.03), ELME000136|ELME000146|ELME000155|ELME000159|PS01208,-
COL2A1_HUMAN,S77N,0.099,-,-,-
COL2A1_HUMAN,S77R,0.210,-,-,-
COL2A1_HUMAN,I80T,0.352,-,-,-
COL2A1_HUMAN,I80V,0.196,-,-,-
COL2A1_HUMAN,D92E,0.469,-,-,-
COL2A1_HUMAN,T95P,0.634,Gain of Intrinsic disorder (Pr = 0.33 | P = 0.03); Gain of O-linked glycosylation at S97 (Pr = 0.27 | P = 7.4e-03); Loss of Proteolytic cleavage at A96 (Pr = 0.18 | P = 4.6e-03), ELME000053|ELME000239,-
COL2A1_HUMAN,Q99K,0.172,-,-,-
COL2A1_HUMAN,G101L,0.918,Loss of B-factor (Pr = 0.32 | P = 3.7e-03); Loss of SUMOylation at K106 (Pr = 0.22 | P = 0.02); Gain of Acetylation at K106 (Pr = 0.20 | P = 0.04); Gain of O-linked glycosylation at S97 (Pr = 0.19 | P = 0.02); Loss of Methylation at K106 (Pr = 0.17 | P = 0.01); Gain of Proteolytic cleavage at A96 (Pr = 0.17 | P = 7.3e-03); Loss of Pyrrolidone carboxylic acid at Q105 (Pr = 0.06 | P = 0.03), None,-
COL2A1_HUMAN,K103L,0.626,Loss of B-factor (Pr = 0.32 | P = 4.4e-03); Gain of Loop (Pr = 0.29 | P = 8.8e-03); Gain of SUMOylation at K106 (Pr = 0.22 | P = 0.02); Loss of Methylation at K103 (Pr = 0.19 | P = 8.2e-03); Loss of Pyrrolidone carboxylic acid at Q105 (Pr = 0.06 | P = 0.03), None,-
COL2A1_HUMAN,Q105R,0.665,Loss of Loop (Pr = 0.31 | P = 4.5e-03); Loss of B-factor (Pr = 0.25 | P = 0.05); Gain of SUMOylation at K106 (Pr = 0.24 | P = 0.01); Loss of Acetylation at K106 (Pr = 0.20 | P = 0.04); Loss of Methylation at K106 (Pr = 0.17 | P = 0.01); Loss of Pyrrolidone carboxylic acid at Q105 (Pr = 0.06 | P = 0.03), ELME000093|ELME000102|PS00009,-
COL2A1_HUMAN,G107A,0.920,Loss of B-factor (Pr = 0.30 | P = 9.5e-03); Gain of SUMOylation at K106 (Pr = 0.26 | P = 7.2e-03); Gain of Methylation at K106 (Pr = 0.17 | P = 8.4e-03); Loss of Pyrrolidone carboxylic acid at Q105 (Pr = 0.06 | P = 0.03), None,-
COL2A1_HUMAN,P109C,0.808,Loss of B-factor (Pr = 0.29 | P = 0.01); Loss of Acetylation at K113 (Pr = 0.27 | P = 7.5e-03); Loss of SUMOylation at K106 (Pr = 0.23 | P = 0.02); Loss of Methylation at K113 (Pr = 0.21 | P = 5.6e-03); Loss of Proteolytic cleavage at D114 (Pr = 0.14 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q105 (Pr = 0.06 | P = 0.02), None,-
COL2A1_HUMAN,G110D,0.912,Loss of Acetylation at K113 (Pr = 0.26 | P = 9.8e-03); Loss of SUMOylation at K106 (Pr = 0.22 | P = 0.02); Loss of Methylation at K113 (Pr = 0.19 | P = 8.3e-03); Gain of Proteolytic cleavage at D114 (Pr = 0.15 | P = 0.01); Loss of Pyrrolidone carboxylic acid at Q105 (Pr = 0.06 | P = 0.03), None,-
COL2A1_HUMAN,D111R,0.711,Loss of Acetylation at K113 (Pr = 0.32 | P = 2.9e-03); Gain of SUMOylation at K106 (Pr = 0.22 | P = 0.02); Loss of Methylation at K113 (Pr = 0.19 | P = 8.1e-03); Loss of Proteolytic cleavage at D114 (Pr = 0.14 | P = 0.02), None,-
COL2A1_HUMAN,D114G,0.775,Gain of Acetylation at K113 (Pr = 0.27 | P = 6.3e-03); Gain of Methylation at K119 (Pr = 0.23 | P = 2.0e-03); Loss of SUMOylation at K113 (Pr = 0.21 | P = 0.03); Loss of Proteolytic cleavage at D114 (Pr = 0.15 | P = 0.01), None,-
COL2A1_HUMAN,I115V,0.079,-,-,-
COL2A1_HUMAN,V116K,0.529,Gain of Acetylation at K113 (Pr = 0.35 | P = 1.9e-03); Gain of B-factor (Pr = 0.30 | P = 2.3e-03); Altered Disordered interface (Pr = 0.28 | P = 0.03); Gain of SUMOylation at V116 (Pr = 0.28 | P = 4.4e-03); Gain of Loop (Pr = 0.27 | P = 0.03); Loss of Methylation at K119 (Pr = 0.21 | P = 5.5e-03); Loss of Proteolytic cleavage at D114 (Pr = 0.15 | P = 0.01), ELME000146|ELME000155,-
COL2A1_HUMAN,K119Q,0.400,-,-,-
COL2A1_HUMAN,D139E,0.237,-,-,-
COL2A1_HUMAN,P163L,0.613,Loss of B-factor (Pr = 0.38 | P = 2.6e-04); Gain of Loop (Pr = 0.28 | P = 0.01), ELME000057|ELME000155,-
COL2A1_HUMAN,G165A,0.934,Loss of B-factor (Pr = 0.32 | P = 4.2e-03), ELME000155,-
COL2A1_HUMAN,P167A,0.665,Loss of B-factor (Pr = 0.35 | P = 1.1e-03); Gain of Loop (Pr = 0.27 | P = 0.03), ELME000155,-
COL2A1_HUMAN,G168Y,0.965,Altered Disordered interface (Pr = 0.37 | P = 7.0e-03); Loss of B-factor (Pr = 0.36 | P = 5.9e-04); Gain of Loop (Pr = 0.29 | P = 7.8e-03); Gain of Sulfation at G168 (Pr = 0.02 | P = 0.03), ELME000155,-
COL2A1_HUMAN,P173H,0.549,Loss of B-factor (Pr = 0.32 | P = 4.7e-03); Gain of Loop (Pr = 0.29 | P = 8.8e-03); Altered Disordered interface (Pr = 0.28 | P = 0.03), ELME000155,-
COL2A1_HUMAN,P173S,0.449,-,-,-
COL2A1_HUMAN,G176I,0.753,Altered Disordered interface (Pr = 0.43 | P = 2.5e-03); Loss of B-factor (Pr = 0.32 | P = 5.1e-03); Gain of Loop (Pr = 0.27 | P = 0.02), ELME000340|PS00008,-
COL2A1_HUMAN,G176T,0.703,Loss of B-factor (Pr = 0.28 | P = 0.02); Gain of Loop (Pr = 0.28 | P = 0.01), PS00008,-
COL2A1_HUMAN,A217S,0.182,-,-,-
COL2A1_HUMAN,P245A,0.263,-,-,-
COL2A1_HUMAN,P245S,0.303,-,-,-
COL2A1_HUMAN,P260A,0.505,Loss of B-factor (Pr = 0.26 | P = 0.05); Gain of Methylation at K262 (Pr = 0.26 | P = 6.3e-04); Loss of Acetylation at K262 (Pr = 0.25 | P = 0.01); Gain of SUMOylation at K259 (Pr = 0.22 | P = 0.02); Gain of Ubiquitylation at K259 (Pr = 0.20 | P = 8.9e-03), None,-
COL2A1_HUMAN,P268L,0.257,-,-,-
COL2A1_HUMAN,S311N,0.234,-,-,-
COL2A1_HUMAN,N317S,0.313,-,-,-
COL2A1_HUMAN,A388G,0.295,-,-,-
COL2A1_HUMAN,P391A,0.330,-,-,-
COL2A1_HUMAN,T455A,0.144,-,-,-
COL2A1_HUMAN,I460V,0.096,-,-,-
COL2A1_HUMAN,G474D,0.913,Gain of Loop (Pr = 0.29 | P = 9.8e-03); Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Methylation at K470 (Pr = 0.23 | P = 3.6e-03); Loss of Acetylation at K470 (Pr = 0.20 | P = 0.04), ELME000155,-
COL2A1_HUMAN,I503V,0.068,-,-,-
COL2A1_HUMAN,F517V,0.799,Altered Disordered interface (Pr = 0.39 | P = 4.7e-03); Gain of Methylation at R515 (Pr = 0.19 | P = 5.4e-03), None,-
COL2A1_HUMAN,S536N,0.255,-,-,-
COL2A1_HUMAN,A544P,0.425,-,-,-
COL2A1_HUMAN,P548N,0.810,Loss of B-factor (Pr = 0.26 | P = 0.04); Altered Metal binding (Pr = 0.10 | P = 0.05); Loss of Methylation at R550 (Pr = 0.10 | P = 0.04), ELME000155|ELME000316,-
COL2A1_HUMAN,V575L,0.129,-,-,-
COL2A1_HUMAN,A595T,0.375,-,-,-
COL2A1_HUMAN,P623A,0.252,-,-,-
COL2A1_HUMAN,A650S,0.179,-,-,-
COL2A1_HUMAN,P673A,0.229,-,-,-
COL2A1_HUMAN,P680A,0.252,-,-,-
COL2A1_HUMAN,P736S,0.582,Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Methylation at K731 (Pr = 0.26 | P = 1.6e-03); Gain of Acetylation at K731 (Pr = 0.23 | P = 0.02); Loss of SUMOylation at K731 (Pr = 0.19 | P = 0.05); Gain of Ubiquitylation at K731 (Pr = 0.17 | P = 0.02); Gain of O-linked glycosylation at S734 (Pr = 0.14 | P = 0.03); Altered Metal binding (Pr = 0.12 | P = 0.04), ELME000085|ELME000155|ELME000239|PS00008,-
COL2A1_HUMAN,A737T,0.141,-,-,-
COL2A1_HUMAN,A761S,0.137,-,-,-
COL2A1_HUMAN,G784A,0.210,-,-,-
COL2A1_HUMAN,G784V,0.381,-,-,-
COL2A1_HUMAN,P808L,0.423,-,-,-
COL2A1_HUMAN,A812T,0.149,-,-,-
COL2A1_HUMAN,P830W,0.684,Loss of B-factor (Pr = 0.37 | P = 4.7e-04); Altered Disordered interface (Pr = 0.30 | P = 0.02); Altered Metal binding (Pr = 0.10 | P = 0.05), ELME000155,-
COL2A1_HUMAN,G831T,0.959,Loss of B-factor (Pr = 0.28 | P = 0.02); Gain of O-linked glycosylation at G831 (Pr = 0.22 | P = 0.01); Altered Metal binding (Pr = 0.10 | P = 0.05), ELME000053|ELME000136|ELME000155|ELME000159|ELME000358,-
COL2A1_HUMAN,A833C,0.428,-,-,-
COL2A1_HUMAN,A836S,0.343,-,-,-
COL2A1_HUMAN,P839Q,0.749,Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of Pyrrolidone carboxylic acid at P839 (Pr = 0.04 | P = 0.05), None,-
COL2A1_HUMAN,A862N,0.417,-,-,-
COL2A1_HUMAN,A862V,0.238,-,-,-
COL2A1_HUMAN,P868L,0.605,Loss of B-factor (Pr = 0.30 | P = 8.5e-03); Loss of O-linked glycosylation at S869 (Pr = 0.12 | P = 0.05); Altered Metal binding (Pr = 0.11 | P = 0.04), ELME000085|ELME000155,-
COL2A1_HUMAN,S869Q,0.652,Gain of B-factor (Pr = 0.25 | P = 0.03); Loss of O-linked glycosylation at S869 (Pr = 0.13 | P = 0.04); Altered Metal binding (Pr = 0.11 | P = 0.04), ELME000085,-
COL2A1_HUMAN,N913S,0.495,-,-,-
COL2A1_HUMAN,P917T,0.421,-,-,-
COL2A1_HUMAN,P937S,0.442,-,-,-
COL2A1_HUMAN,P938S,0.482,-,-,-
COL2A1_HUMAN,D962S,0.383,-,-,-
COL2A1_HUMAN,P964A,0.233,-,-,-
COL2A1_HUMAN,S1001T,0.528,Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Methylation at K1006 (Pr = 0.26 | P = 1.4e-03); Loss of Acetylation at K1006 (Pr = 0.24 | P = 0.02); Loss of O-linked glycosylation at S1001 (Pr = 0.18 | P = 0.03); Loss of Ubiquitylation at K1006 (Pr = 0.15 | P = 0.05), ELME000085|ELME000239,-
COL2A1_HUMAN,T1028S,0.267,-,-,-
COL2A1_HUMAN,A1031S,0.108,-,-,-
COL2A1_HUMAN,P1046S,0.850,Loss of B-factor (Pr = 0.28 | P = 0.02); Altered Metal binding (Pr = 0.13 | P = 0.03); Loss of Methylation at R1048 (Pr = 0.10 | P = 0.04), ELME000085|ELME000321|PS00005|PS00006,-
COL2A1_HUMAN,A1051V,0.363,-,-,-
COL2A1_HUMAN,T1061A,0.229,-,-,-
COL2A1_HUMAN,A1069T,0.226,-,-,-
COL2A1_HUMAN,P1076S,0.690,Gain of Loop (Pr = 0.32 | P = 2.4e-03); Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of O-linked glycosylation at P1076 (Pr = 0.15 | P = 0.03), ELME000085|ELME000136|ELME000155|ELME000159|ELME000239,-
COL2A1_HUMAN,T1082V,0.267,-,-,-
COL2A1_HUMAN,P1124Q,0.346,-,-,-
COL2A1_HUMAN,A1153T,0.179,-,-,-
COL2A1_HUMAN,N1204S,0.211,-,-,-
COL2A1_HUMAN,P1228Q,0.043,-,-,-
COL2A1_HUMAN,G1247D,0.296,-,-,-
COL2A1_HUMAN,G1247N,0.102,-,-,-
